Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00906373 · ClinicalTrials.gov registry record · Phase 2
A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT00906373 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 47 participants.
The verdict
NCT00906373, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
To determine if IMC-A12 given in combination with Sorafenib is safe and effective for participants with advanced liver cancer.
Interventions
- DRUG Sorafenib
- BIOLOGICAL IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)
- BIOLOGICAL IMC-A12 (cixutumumab) - 20 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2009-05 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00906373
The ClinicalTrials.gov registry entry for NCT00906373 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sorafenib is the first listed.
NCT00906373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00906373 about?
NCT00906373 is a clinical study titled "A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver". To determine if IMC-A12 given in combination with Sorafenib is safe and effective for participants with advanced liver cancer.
What is the current status of trial NCT00906373?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2009-05. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00906373?
The interventions under investigation include: Sorafenib (DRUG), IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg) (BIOLOGICAL), IMC-A12 (cixutumumab) - 20 mg/kg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00906373?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.